Benjamin Kopecky, MD
Basic profileAdvanced Heart Failure and Transplant Cardiology
Benjamin Kopecky is a Cardiology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12605 E 16th Ave
Aurora, CO 800452545
Telephone
720-848-0000Provider last certified this registry record 30 Nov 2023.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20231 payment
- Paragonix Technologies, Inc.Program year20221 payment
- Abbott LaboratoriesProgram year20222 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
79.4%Angiotensin receptor blocker (ARB)27.7%Losartan Potassium100%Part D≥14 patientsBeta blocker23.9%Carvedilol100%Part D≥12 patients+ 2 more classes in this area
Cancer & immunology
20.6%Calcineurin inhibitor20.6%Tacrolimus100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2024–2026 per NIH RePORTER. The latest:
- Leveraging targeted cell therapy to promote heart transplant tolerance through topical application of a nanoparticle infused polymeric membrane
University of Colorado Denver
FY2026$624,000R21EB038487 - Dissecting the Role of Donor CCR2- Macrophages During Acute Cellular Rejection After Heart Transplantation
University of Colorado Denver
FY2026$151,457K08HL159359 - Dissecting the Role of Donor CCR2- Macrophages During Acute Cellular Rejection After Heart Transplantation
University of Colorado Denver
FY2025$151,457K08HL159359
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”